BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27035988)

  • 1. Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy.
    Zhang Y; Yang Y; Hosaka K; Huang G; Zang J; Chen F; Zhang Y; Samani NJ; Cao Y
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4158-63. PubMed ID: 27035988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.
    Yang Y; Zhang Y; Cao Z; Ji H; Yang X; Iwamoto H; Wahlberg E; Länne T; Sun B; Cao Y
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):12018-23. PubMed ID: 23818623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.
    Cao Y
    Nat Rev Endocrinol; 2014 Sep; 10(9):530-9. PubMed ID: 25048037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.
    Yang Y; Zhang Y; Iwamoto H; Hosaka K; Seki T; Andersson P; Lim S; Fischer C; Nakamura M; Abe M; Cao R; Skov PV; Chen F; Chen X; Lu Y; Nie G; Cao Y
    Nat Commun; 2016 Sep; 7():12680. PubMed ID: 27580750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells.
    Curtarello M; Zulato E; Nardo G; Valtorta S; Guzzo G; Rossi E; Esposito G; Msaki A; Pastò A; Rasola A; Persano L; Ciccarese F; Bertorelle R; Todde S; Plebani M; Schroer H; Walenta S; Mueller-Klieser W; Amadori A; Moresco RM; Indraccolo S
    Cancer Res; 2015 Jan; 75(1):120-33. PubMed ID: 25381153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
    Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage.
    Koh YJ; Kim HZ; Hwang SI; Lee JE; Oh N; Jung K; Kim M; Kim KE; Kim H; Lim NK; Jeon CJ; Lee GM; Jeon BH; Nam DH; Sung HK; Nagy A; Yoo OJ; Koh GY
    Cancer Cell; 2010 Aug; 18(2):171-84. PubMed ID: 20708158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
    Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
    Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
    Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
    Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
    Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.
    Greenberg JI; Cheresh DA
    Expert Opin Biol Ther; 2009 Nov; 9(11):1347-56. PubMed ID: 19761418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.